Who makes MY006 Selected Dose?

MY006 Selected Dose is developed by Mabylon AG.

What development phase is MY006 Selected Dose in?

MY006 Selected Dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

MY006 Selected Dose

Mabylon AG · Phase 1 active Small molecule

At a glance

Generic name	MY006 Selected Dose
Sponsor	Mabylon AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MY006 Selected Dose CI brief — competitive landscape report
MY006 Selected Dose updates RSS · CI watch RSS
Mabylon AG portfolio CI